Figure 1. Selected highlights in the development of immunotherapy. Figure 3. A schematic picture showed the improved CIK therapy. CIK, cytokine-induced killer; TA, tumor antigen; CAR, chimeric antigen ...

Cytokine Release Syndrome (CRS) is a major concern in CAR-T therapy. How do you approach the grading and management of CRS? Which strategies have you found most effective for reducing the severity of ...

Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's ...

Charles River’s Cell Therapy Flex Platform is an off-the-shelf solution for cell therapy process development. Credit: Stock-Asso/Shutterstock. Charles River Laboratories and Akron Bio have announced ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Charles River Laboratories and Akron Bio have announced the integration of the latter’s closed system solutions (CSS) liquid cytokines into Charles River’s Cell Therapy Flex platform for ...

Merck seems to have identified cytokines as a fertile ground for exploration, as the Synthekine deal follows its earlier $1.9 billion takeover of Pandion Therapeutics, which is developing a ...

Moreover, patients who had undergone prior CD19-directed CAR T-cell therapy had a complete response ... causing graft-versus-host disease, severe cytokine release syndrome, or immune effector ...

In the quest for longevity and reversing biological age, Bryan Johnson, a tech entrepreneur known for his extensive efforts ...